Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI
unknown
📅 Published: 2026-03-16 21:10
📰 Source: Yahoo
📝 Words: 56
📝 Article Content
Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma. The company hopes to […]
📄 Summary
Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma. The company hopes to […]
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:43
Updated At:
2026-03-20 04:09:43
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A